Bristol-Myers Squibb (NYSE:BMY) Stock Price Up 1.2%

Bristol-Myers Squibb (NYSE:BMY) rose 1.2% during mid-day trading on Monday . The company traded as high as $48.86 and last traded at $48.85. Approximately 3,402,161 shares changed hands during mid-day trading, a decline of 79% from the average daily volume of 15,830,479 shares. The stock had previously closed at $48.28.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of analyst reports. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Wells Fargo & Company cut their target price on shares of Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 6th. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday. Finally, Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $61.12.

Bristol-Myers Squibb Stock Down 0.5 %

The company has a market cap of $97.83 billion, a P/E ratio of 12.51, a price-to-earnings-growth ratio of 1.46 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. The business’s fifty day moving average is $51.27 and its two-hundred day moving average is $51.62.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.15. The company had revenue of $11.48 billion during the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the company earned $1.82 EPS. Equities analysts predict that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a $0.60 dividend. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 4.97%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 62.18%.

Institutional Investors Weigh In On Bristol-Myers Squibb

Several large investors have recently added to or reduced their stakes in the stock. True Wealth Design LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $26,000. Coppell Advisory Solutions Corp. purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $31,000. Coppell Advisory Solutions LLC purchased a new stake in shares of Bristol-Myers Squibb in the 2nd quarter worth approximately $28,000. Live Oak Investment Partners purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $33,000. Finally, OFI Invest Asset Management purchased a new stake in shares of Bristol-Myers Squibb in the 3rd quarter worth approximately $25,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.